Cambridge Innovation Capital is an established VC firm embedded in the UK technology ecosystem with privileged access to the University of Cambridge. The firm manages over £600m of capital and invests across deep tech and life sciences.
The round was co-led by AlbionVC and Cambridge Innovation Capital to support commercial expansion and research.
"There’s never been a greater need to effectively deploy ML models in enterprise, and this fresh capital injection will ensure our customers have the tools they need to achieve their goals."
The financing round was co-led by Tencent and Legal & General to support international expansion and product development.
"Genomic medicine is revolutionising healthcare, transforming outcomes for patients by providing clinicians with fast, accurate and early diagnoses and the information needed to provide life-changing answers for their patients, improving wellbeing and disease management. This new funding will allow us to build on our established foundation in rare disease and bring the power of our platform to new indications and new markets. We welcome our new investors to Congenica and are grateful to our existing investors for their continued support."
The funding round was led by nChain and Cambridge Innovation Capital.
"Businesses have realised that advanced analytics and rapid innovation is the key to building competitive advantage in a data-driven world, so where billion row queries that took hours were once acceptable, the market now demands trillions of rows and speed-of-thought results. Aside from performance and scale, database technology needs to be built with the future of the connected world in mind – providing flexibility and cost predictability, even as the demands for big data continues to grow."
The record European medtech financing was backed by new US investors and existing partners including LGT and Cambridge Innovation Capital.
"We are pleased to welcome new US investors whose calibre and scale are reflective of the scale of CMR's mission to transform surgery. I would also like to thank our existing investors for their long-term commitment in supporting this company to achieve its global mission. The significant capital injection in a UK scale-up reconfirms my belief that the Cambridge eco system has fostered a unique pool of diverse talents and competencies that will help drive our innovation in the years ahead. With new and existing investors onboard, CMR is well-placed to make surgical robotics accessible for all."
The round was led by BGF with participation from Parkwalk, Cambridge Enterprise, and Cambridge Innovation Capital.
"Parkwalk are delighted to continue to support the ground breaking technology from Dr Ken Smith’s laboratory at Addenbrookes, which enables the prognosis of IBD and an earlier clinical decision as to the correct drug treatment. This will significantly improve clinical outcomes and enhance patient welfare. The team at PredictImmune have done a magnificent job in productising the technology and are now taking the tests on their commercial pathway. We look forward to seeing the platform extended to benefit clinical outcomes in further diseases."
